UNLOXCYT
Generic: cosibelimab
- NDC
- 70095-130
- RxCUI
- 2717518
- Route
- INTRAVENOUS
- ICD-10 indication
- C44.92
Affordability Check
How much will you actually pay for UNLOXCYT?
In 30 seconds, see every legitimate way to afford UNLOXCYT — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.
About UNLOXCYT
What is this medication? Unloxcyt is not a recognized or standard prescription medication currently listed in major pharmaceutical databases or approved by regulatory agencies such as the FDA. Because this specific name does not match any known brand-name or generic drugs, there is no clinical data available regarding its therapeutic indications, mechanisms of action, or safety profile. It is possible that the name provided is a misspelling of another pharmaceutical product or refers to a substance that is not widely marketed.
If you have been prescribed a medication with a name similar to Unloxcyt, it is essential to consult with a licensed healthcare provider or pharmacist to verify the correct spelling and intended use. Using an unidentified or incorrectly named medication can pose significant risks to your health. Always refer to the official medication guide and packaging information provided by your pharmacy to ensure you are receiving the appropriate treatment for your medical condition.
Copay & patient assistance
- Patient Copay Amount: As little as $0
- Maximum Annual Benefit Limit: $10,000 per calendar year for patients in "maximizer" plans; standard limit is Not Publicly Available
- Core Eligibility Restrictions: Must have commercial health insurance; must be a resident of the United States, Puerto Rico, Guam, or the Virgin Islands; must be at least 18 years of age; diagnosis must be an on-label ICD-10-CM code; excludes patients covered by federal or state government-funded programs (e.g., Medicare, Medicaid, TRICARE, VA, DoD)
- RxBIN, PCN, and Group numbers: Not Publicly Available
External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.
Compare pricing elsewhere
RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.
Cost Plus Drug Company
Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for cosibelimab.
Browse Cost Plus medications →
GoodRx
Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.
Lookup UNLOXCYT →
NeedyMeds
Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.
Search for cosibelimab →
RxAssist
PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.
Search PAPs →
We deep-link because transparency helps patients. None of these partners pay RxCopays.
Conditions we've indexed resources for
Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.
Prior authorization & coverage
| Payer | PA | Step therapy | Copay tier |
|---|---|---|---|
— Medicare Part D | — | — | — |
Related drugs
EVEROLIMUS
Treats same condition · Everolimus
AVMAPKI FAKZYNJA CO-PACK
Treats same condition · avutometinib potassium and defactinib hydrochloride
Fludeoxyglucose F18
Treats same condition · Fludeoxyglucose F18
Portrazza
Treats same condition · necitumumab
Pilocarpine Hydrochloride
Treats same condition · Pilocarpine Hydrochloride
TEPADINA
Treats same condition · THIOTEPA
AVGEMSI
Treats same condition · Gemcitabine
CLENPIQ
Treats same condition · SODIUM PICOSULFATE, MAGNESIUM OXIDE, and ANHYDROUS CITRIC ACID
Niva Thyroid
Treats same condition · thyroid, porcine
Kisunla
Treats same condition · donanemab-azbt
How this page is sourced
- Drug identity verified against openFDA NDC Directory.
- Label text (when shown) originates from NLM DailyMed.
- Copay and assistance URLs verified periodically; if you hit a broken link, tell us.